Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2011; 17(43): 4747-4756
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4747
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4747
Table 3 Therapeutic algorithm
| Patients with clear cell renal carcinoma | First-line therapy | Second-line therapy | |
| Without previous treatment | Prognostic grade: favorable or intermediate prognosis | Sunitinib or | IL-2 high dose or |
| Bevacizumab + interferon α | clinical trial | ||
| Prognostic grade: poor | Temsirolimus | Sunitinib or | |
| clinical trial | |||
| With previous treatment | With cytokine | Sorafenib | Sunitinib |
| With multitargeted therapy | Everolimus | Tyrosine kinase inhibitor or clinical trial | |
| Patients with not clear cell renal carcinoma | Temsirolimus | Sunitinib or | |
| sorafenib | |||
- Citation: Ballarin R, Spaggiari M, Cautero N, Ruvo ND, Montalti R, Longo C, Pecchi A, Giacobazzi P, Marco GD, D’Amico G, Gerunda GE, Benedetto FD. Pancreatic metastases from renal cell carcinoma: The state of the art. World J Gastroenterol 2011; 17(43): 4747-4756
- URL: https://www.wjgnet.com/1007-9327/full/v17/i43/4747.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i43.4747